Back
Allogene Therapeutics 10K Form
Sell
22
ALLO
Allogene Therapeutics
Last Price:
$1.82
Seasonality Move:
-11%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive ALLO News And Ratings
See the #1 stock for the next 7 days that we like better than ALLO
ALLO Financial Statistics
Sales & Book Value
| Annual Sales: | $95K |
|---|---|
| Cash Flow: | $-44.5M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $2.21 |
| Price / Book: | 0.82 |
Profitability
| EPS (TTM): | -1.56000 |
|---|---|
| Net Income (TTM): | $-283.4M |
| Gross Margin: | -- |
| Return on Equity: | -52.73% |
| Return on Assets: | -42.25% |
Allogene Therapeutics Earnings Forecast
Key Allogene Therapeutics Financial Ratios
-
The Research & Development expenses have been 255,698.95% of Revenue.
-
Per Share Earnings over the last 6 years have been positive in 3 years.
Allogene Therapeutics Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | ALLO |
| CUSIP: | 019770 |
| Website: | allogene.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 12.8 |
| Quick Ratio: | 12.46 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
ALLO Technical Analysis vs Fundamental Analysis
Sell
22
Allogene Therapeutics (ALLO)
is a Sell
Is Allogene Therapeutics a Buy or a Sell?
-
Allogene Therapeutics stock is rated a SellThe current Allogene Therapeutics [ALLO] share price is $1.82. The Score for ALLO is 22, which is 56% below its historic median score of 50, and infers higher risk than normal.